Early-Phase Immunotherapy Trial Results Lend Further Support for ctDNA as Surrogate Endpoint
Researchers from Princess Margaret Cancer Center demonstrated that a decrease in ctDNA within four weeks after immunotherapy treatment was associated with response and survival.
Lucence Liquid Biopsy Test to Receive Medicare Reimbursement in Lung Cancer
Lucence's amplicon-based LiquidHallmark liquid biopsy assay will now be covered under a finalized local coverage determination from Medicare contractor Palmetto.
Natera Files Second Patent Infringement Suit Against NeoGenomics Subsidiary Inivata
The suit was filed the same day Natera received a new patent covering its patient-specific residual cancer testing and monitoring methods.
Multiple Myeloma Researchers Chip Away at Why Some Patients Relapse Quickly After CAR T-Cell Therapy
Recent and ongoing studies suggest differences in patients' tumor microenvironment and cell-free DNA could be why some have enduring responses and others quickly relapse.
The EGFR C797X mutation is the most common on-target resistance mechanism to EGFR TKIs, and drugmakers behind fourth-generation inhibitors are trying to tackle it.